BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

BioXcel Therapeutics (BTAI) Misses Q3 EPS by 45c

November 14, 2023 7:03 AM EST

BioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($1.72), $0.45 worse than the analyst estimate of ($1.27). Revenue for the quarter came in at $341 thousand versus the consensus estimate of $625.81 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

... More